If affordable medication access with minimal friction is your primary goal, MEDVi delivers
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
However, there are several other benefits to switching from Saxenda to Wegovy, including convenience, effectiveness, and cardiovascular risk reduction
Hair loss is listed as a common side effect of Mounjaro, reported in up to 5.7% of trial participants higher than Wegovys 3%.Mounjaro Hair Loss Book a Consultation If youre losing hair on Wegovy, the first step is understanding why and whether it will resolve on its own or needs treatment